| Literature DB >> 27128894 |
Michał Dąbrowski1, Kazimierz Obremski2, Magdalena Gajęcka3, Maciej Tadeusz Gajęcki4, Łukasz Zielonka5.
Abstract
Zearalenone and deoxynivalenol are secondary metabolites of fungi of the genus Fusarium. The presence of mycotoxins in cereals and the resulting contamination of feeds and foods pose health risks for animals and humans. The dangers associated with high doses of mycotoxins have been extensively researched but very little is known about NOAEL (No Observed Adverse Effect Level) doses or exposure to a combination of mycotoxins (mixed mycotoxicoses). The aim of this study was to determine the effects of six-week exposure to NOAEL doses of individual and combined mycotoxins on the subpopulations of CD4⁺8(-), CD4(-)8⁺ and CD4⁺8⁺ lymphocytes in the peripheral blood of pigs. The experiment was performed on 72 gilts with average body weight of 25 kg, divided into three experimental groups (E1, E2 and E3, administered zearalenone (ZEN), deoxynivalenol (DON) and ZEN + DON, respectively, on a daily basis) and a control group (C) receiving placebo. Changes in lymphocyte subpopulations were evaluated by flow cytometry at weekly intervals (experimental days 7, 14, 21, 28, 35 and 42). A linear increase in the percentage of CD4⁺8⁺ lymphocytes was highly correlated with time (r = 0.682) in group C. The correlations and linear increase in the above subpopulation were disrupted in the remaining groups. In group E3, a statistically significant (p < 0.05) decrease in CD4⁺8⁺ counts was observed in week 5, which could point to a transient depletion of regulatory mechanisms of immune responses. The noted results also suggest that in mixed mycotoxicosis, ZEN and DON exerted stronger immunomodulatory effects.Entities:
Keywords: CD4−8+ and CD4+8+; deoxynivalenol; flow cytometry; lymphocytes CD4+8−; pig; zearalenone
Mesh:
Substances:
Year: 2016 PMID: 27128894 PMCID: PMC6272943 DOI: 10.3390/molecules21050557
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Average percentages of lymphocyte subpopulations + SD.
| Group | Week of the Experiment | CD4+8− | SD | CD4+8+ | SD | CD4−8+ | SD |
|---|---|---|---|---|---|---|---|
| C | 1 | 10.233 | 6.785 | 9.133 a | 2.867 | 32.866 | 20.947 |
| 2 | 17 | 5.185 | 14.5 | 1.868 | 32.833 | 2.836 | |
| 3 | 11.1 | 1.969 | 15.1 | 3.915 | 32.4 | 6.158 | |
| 4 | 13.9 | 5.828 | 12.233 | 1.001 | 33 | 9.18 | |
| 5 | 9.066 | 0.404 | 22.066 a,b | 4.623 | 36.666 | 5.342 | |
| 6 | 13.566 | 2.409 | 20.5 a | 6.378 | 29.6 | 1.967 | |
| E1 | 1 | 9.966 | 7.755 | 20.6 | 4.132 | 38.966 | 11.403 |
| 2 | 11.133 | 5.229 | 16.666 | 1.357 | 30.166 | 2.983 | |
| 3 | 14.366 | 2.0550 | 17.066 | 2.809 | 35.733 | 2.358 | |
| 4 | 10.833 | 0.896 | 12.666 | 3.557 | 36 | 4.853 | |
| 5 | 7.833 | 1.365 | 20.2 | 4.590 | 36.9 | 2.882 | |
| 6 | 10.533 | 1.921 | 18.566 | 11.809 | 29.833 | 5.75 | |
| E2 | 1 | 8.466 | 3.695 | 14.5 | 2.364 | 31.433 | 3.234 |
| 2 | 12.266 | 1.6258 | 12.933 | 1.975 | 34.266 | 5.783 | |
| 3 | 14.033 | 2.891 | 16.933 | 0.351 | 32.5 | 6.755 | |
| 4 | 8.066 | 3.789 | 17.8 | 1.4 | 47.2 | 16.629 | |
| 5 | 12.333 | 3.636 | 14.066 | 4.086 | 29.8 | 8.150 | |
| 6 | 13.733 | 2.837 | 14.533 | 2.65 | 31.966 | 6.469 | |
| E3 | 1 | 9.766 | 0.7571 | 12.8 | 7.692 | 31.233 | 12.182 |
| 2 | 15.133 | 1.778 | 14.833 | 1.361 | 34.766 | 5.832 | |
| 3 | 10.066 | 1.847 | 12.5 | 5.068 | 32.833 | 11.657 | |
| 4 | 11.766 | 3.181 | 15.766 | 7.5975 | 28.833 | 12.828 | |
| 5 | 12.8 | 0.9539 | 10.633 b | 1.2503 | 35.066 | 8.146 | |
| 6 | 13.8 | 4.330 | 15.9 | 2.688 | 26.5 | 6.908 |
a Statistically significant differences within the group (p ≤ 0.05). b Statistically significant differences between the groups (p ≤ 0.05).
Figure 1The percentage of individual subpopulation of lymphocytes in the fifth week of the experiment.
Figure 2Individual and mean percentages of CD4+8+ lymphocyte subpopulations in group C.
Figure 3Individual and mean percentages of CD4+8+ lymphocyte subpopulations in group E1.
Figure 4Individual and mean percentages of CD4+8+ lymphocyte subpopulations in group E2.
Figure 5Individual and mean percentages of CD4+8+ lymphocyte subpopulations in group E3.